LRP6 and cancer: Interestingly, unlike HEK293 cells where the STF reporter activity can be inhibited fully by anti-LRP6 antibodies (mono or bispecific, with the difference in IC50 but not maximum level of inhibition), we observed about 50% suppression of Wnt/β-catenin reporter activity in cancer cells.